The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Improved Biomarkers and Clinical Outcome Measures, 2017Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in Parkinson's Disease
Study Rationale:
This project will test a new idea for measuring the severity of Parkinson's disease (PD). The brain acts as if it can store each dose of levodopa (L DOPA) for a short period of time... -
Research Grant, 2017Improving Participation in Clinical Trials in Individuals with Atypical Parkinsonian Syndromes through Virtual Research Visits (ImPaCT-Atypical)
Objective/Rationale:
The Michael J. Fox Foundation's Fox Trial Finder is designed to facilitate and increase the participation of individuals with Parkinson's disease (PD) and degenerative... -
Therapeutic Pipeline Program, 2017Advancing Neuroprotective Protein Regulators Toward the Clinical Candidate Phase
Study Rationale:
Addex Pharmaceuticals has developed drug discovery tools that can be used to screen its small molecule compound library for positive allosteric modulators (protein regulators) of TrkB... -
Therapeutic Pipeline Program, 2017Protein Homeostasis and the Ubiquitination Pathway in Parkinson's Disease
Study Rationale:
Parkinson's disease (PD) involves accumulation of toxic proteins in cells in specific areas of the brain. These cells normally have protective mechanisms to remove these toxic... -
Improved Biomarkers and Clinical Outcome Measures, 2017Using Automatic Acoustic Speech Analysis and REM Sleep Behavior Disorder to Detect Individuals at High Risk of Parkinson's Disease and Other Alpha-synucleinopathies
Study Rationale:
Speech is an important indicator of motor function and movement coordination and can be extremely sensitive to the progression of neurologic diseases. The aim of this project is to... -
Oligomeric & pS129 Assay LEAPS, 2017Quantification of S129 Phosphorylated Alpha-synuclein Using the AlphaLISA® Immunoassay Platform
Study Rationale:
The alpha-synuclein protein is a key player in Parkinson’s disease (PD). Our ability to understand how this protein impacts the health of neurons in the brain is directly related to...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.